Corona Remedies Shines Bright: Strong Q2 & H1 FY26 Performance Driven by Chronic Portfolio and Strategic Expansion

CORONA Remedies Limited, an India-focused branded pharmaceutical company, has reported a robust financial performance for the second quarter and half year ended September 30, 2025 (Q2 & H1 FY26). The company, which recently listed on the stock exchanges on December 15, 2025, showcased significant growth across key financial metrics, underscoring its strategic focus on chronic and semi-chronic therapeutic segments. This period marks a confident stride for CORONA Remedies, reinforcing its position in the competitive Indian pharmaceutical market.

For Q2 FY26, CORONA Remedies posted a revenue from operations of INR 361.1 crore, reflecting a substantial 15.1% year-on-year growth. The momentum continued into the first half of the fiscal year, with H1 FY26 revenue reaching INR 707.7 crore, a 17.0% increase over H1 FY25. This growth was primarily fueled by the company's strong presence in chronic therapies, which contribute approximately 70% to its total revenues. The management highlighted that CORONA has consistently outpaced the Indian pharmaceutical market, growing at more than 1.5 times the IPM, and is recognized as the fastest-growing pharmaceutical company among the top 30 as per MAT September '25 data.

Operational Excellence and Strategic Thrust

The company's operational efficiency was evident in its EBITDA performance. For Q2 FY26, EBITDA stood at INR 78.5 crore, marking a 17.4% year-on-year growth, with EBITDA margins improving by 40 basis points to 21.7%. The H1 FY26 EBITDA saw an even more impressive 27.4% growth, reaching INR 148.3 crore, with margins expanding by 170 basis points to 20.9%. Profit After Tax (PAT) also demonstrated robust growth, with Q2 FY26 PAT at INR 52.3 crore (21.8% Y-o-Y growth) and H1 FY26 PAT at INR 98.5 crore (35.1% Y-o-Y growth). The annualized Return on Equity (ROE) for H1 FY26 was 31.1%, and Return on Capital Employed (ROCE) was 49.7%, indicating efficient capital utilization.

CORONA Remedies attributes its success to a disciplined 'triple C' philosophy: Culture, Courage, and Commitment. This framework emphasizes ruthless execution, internal promotion, adaptability, accepting mistakes for improvement, pursuing inorganic growth opportunities, and a steadfast commitment to global quality products and long-term sustainable growth. The company's strong cash flow generation, with OCF to EBITDA at a healthy 76.5% and net working capital days at 23, further underscores its financial prudence.

Expanding Horizons: New Therapies and Global Footprint

Looking ahead, CORONA Remedies is strategically expanding its product portfolio and geographical presence. The company is poised to enter new therapeutic areas such as infertility, nephrology, CNS, oncology, and dermatology. A significant move in this direction was the acquisition of seven brand trademarks from Bayer Zydus Pharma in July 2025, specifically targeting the infertility segment. A dedicated team for infertility is expected to be launched within the next three to four months, aiming to strengthen the company's position in women's healthcare.

In terms of manufacturing, CORONA operates two WHO GMP certified facilities, one in Gujarat and another in Himachal Pradesh. The Gujarat facility also holds EU GMP accreditation. The company is also investing in backward integration through La Chandra Pharma Lab for hormonal API manufacturing, which will support its international expansion plans. An EU GMP approvable plant for international business is expected to commence operations by Q2 or Q3 FY27, with WHO approval anticipated by Q4 FY27. This expansion targets global markets, excluding the US and Japan initially, with an aim to achieve an 8-9% higher single-digit Compound Annual Growth Rate (CAGR) from international business within a couple of years.

Commitment to Sustainability and Future Outlook

CORONA Remedies is also deeply committed to Environmental, Social, and Governance (ESG) principles. The company has an existing 1.3 MW solar power plant and plans to invest in a 4.25 MW solar park to significantly reduce electricity costs. Environmental protection initiatives include tree plantation, an effluent treatment plant for zero liquid discharge, and promoting sustainable practices. Socially, CORONA provides financial assistance for sports and education, organizes blood donation camps, invests in employee training, and promotes gender equality, with 40% of the workforce at its Solan plant being female. The World Bank Group awarded CORONA with an EDGE Advance Certificate for energy and water saving measures, and the company holds an A+ credit rating.

Management has provided a clear guidance, targeting a 15% revenue growth and 20% PAT or EPS growth year-on-year for the next three to four years. The company plans to expand its Medical Representative (MR) force by 5-7% annually to deepen market penetration. With a strong foundation, strategic growth initiatives, and a commitment to sustainability, CORONA Remedies is well-positioned for sustained growth and value creation for its stakeholders.